On May 20, 2016 TG Therapeutics, Inc. (Nasdaq:TGTX), reported that updated data has been selected for presentation at the upcoming 21st European Hematology Association (EHA) (Free EHA Whitepaper) Annual Congress, to be held from June 9 – 12, 2016 in Copenhagen, Denmark (Filing, 8-K, TNI BioTech, MAY 20, 2016, View Source [SID:1234512626]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentations Include:
Title: Long-term follow-up of the next generation PI3K-delta inhibitor TGR-1202 demonstrates safety and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab
Abstract Number: P207
Presentation Date & Time: Friday, June 10, 2016 5:15PM – 6:45PM CEST
Location: Poster Hall H
Presenter: Anthony Mato, MD, University of Pennsylvania, Philadelphia, PA
Title: Long-term follow-up of the next generation PI3Kδ inhibitor TGR-1202 demonstrates safety and high response rates in NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab
Abstract Number: P315
Presentation Date & Time: Friday, June 10, 2016 5:15PM – 6:45PM CEST
Location: Poster Hall H
Presenter: Owen A. O’Connor, MD, PhD, Columbia University Medical Center, NY, NY
Title: Preliminary results of a Phase I/Ib study of ibrutinib in combination with TGR-1202 in patients with relapsed/refractory CLL or MCL
Abstract Number: E1053
E-poster Presentation
Presenter: Matthew S. Davids MD, Dana-Farber Cancer Institute, Boston, MA
A copy of the EHA (Free EHA Whitepaper) abstracts were made available yesterday, May 19, 2016 through the EHA (Free EHA Whitepaper) meeting website at www.ehaweb.org. Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com.